(2023). Hematological Effects of Antiviral Drugs for Hepatitis C Virus. The Egyptian Journal of Hospital Medicine, 92(1), 6455-6458. doi: 10.21608/ejhm.2023.315683
. "Hematological Effects of Antiviral Drugs for Hepatitis C Virus". The Egyptian Journal of Hospital Medicine, 92, 1, 2023, 6455-6458. doi: 10.21608/ejhm.2023.315683
(2023). 'Hematological Effects of Antiviral Drugs for Hepatitis C Virus', The Egyptian Journal of Hospital Medicine, 92(1), pp. 6455-6458. doi: 10.21608/ejhm.2023.315683
Hematological Effects of Antiviral Drugs for Hepatitis C Virus. The Egyptian Journal of Hospital Medicine, 2023; 92(1): 6455-6458. doi: 10.21608/ejhm.2023.315683
Hematological Effects of Antiviral Drugs for Hepatitis C Virus
Background: Direct-acting antivirals (DAAs) have replaced interferon-based therapies in the treatment of HCV infection. Despite general success, treating some patient populations with antiviral medication is still difficult. Even though serious adverse effects are uncommon, they can nonetheless occur, particularly in individuals with advanced liver disease. Objective: Our goal was to assess the haematological effects of antiviral medications in chronic HCV patients. Patients and methods: The total number of patients included, were 50. Males represented 27 (54.0%) of total patients and females represented 23 (46.0%). The mean age of the studied patients was 46.24 ± 9.67 years. All patients were thoroughly examined, and full labs were obtained before start and 3 & 6 months after treatment. Results: SVR was 100% in our research (P-value 0.001). Three- and six-months following therapy, there was a statistically significant increase in mean corpuscular volume (MCV) and hematocrit (HCT) (P-values = 0.035 and 0.048, respectively). Three months after starting therapy, haemoglobin levels rose, although the increases weren't statistically significant (P-value = 0.719). Six months after starting therapy, haemoglobin showed a statistically significant improvement (P-value = 0.019). Six months following the start of therapy, the platelet count increased statistically significantly (P-value = 0.038). Six months following therapy, our study found statistically significant reductions in total bilirubin (P-value = 0.001), ALT (P-value = 0.012), AST (P-value = 0.001), and AFP (P-value = 0.002). Conclusions: Results indicated that the sofosbuvir-daclatasvir medication combination is safe for Egyptians and that it plays a key role in the treatment of HCV with fewest side effects.
View on SCiNiTO
Top